Recommended Starting Dilutions:
Western blot: Use at 1 to 2 μg/ml
Optimal dilutions should be determined experimentally by the researcher.
K562 or 3T3 cell lysate can be used as a positive control and a band at approximately 23 kDa can be detected. A lower band at approximately 16 kDa was detected in MOLT4 and U937 cells, which may represent the PUMA-beta form.
PBS with 0.02% sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1mg/ml(Please refer to the vial label for the specific concentration.)
Synthetic peptide (PLPRGHRAPEMEPN) corresponding to amino acids 180 to 193 of human PUMA-a (1).
Immunogen affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
BBC3, 605854, PUMA, PUMA/JFY1, 27113, Q9BXH1, JFY1
Apoptosis is related to many diseases and development. The p53 tumor-suppressor protein induces apoptosis through transcriptional activation of several genes. A novel p53 inducible pro-apoptotic gene was identified recently and designated PUMA (for p53 upregulated modulator of apoptosis) and bbc3 (for Bcl-2 binding component 3) in human and mouse. PUMA/bbc3 is one of the pro-apoptotic Bcl-2 family members including Bax and Noxa, which are also transcriptional targets of p53. The PUMA gene encodes two BH3 domain-containing proteins termed PUMA-a and PUMA-b. PUMA proteins bind Bcl-2, localize to the mitochondria, and induce cytochrome c release and apoptosis in response to p53. PUMA may be a direct mediator of p53-induced apoptosis.